Related Experiment Video
Updated: Mar 18, 2026
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer
Kimihiro Yamashita1, Hiroshi Hasegawa2, Mitsugu Fujita3
1Department of Surgery, Division of Gastrointestinal Surgery, Kobe University Graduate School of Medicine, Kobe, Japan kiyama@med.kobe-u.ac.jp.
Background/Aim:
For the application of invariant natural killer T (iNKT) cells in cancer therapy, the CD40-CD40L interaction is indispensable in administering alpha-galactosylceramide (αGalCer). We hypothesized that CD40 plays an important role in dendritic cells (DC) pulsed with αGalCer (DCGs) in the treatment of lung metastases.
Materials And Methods:
Wild-type (WT) and CD40(-/-) mice were treated with DCGs isolated from WT or CD40(-/-) mice in a B16F10 lung metastases model and NK and NKT cell activity in lungs and the spleen were examined.
Results:
DCG treatment improved WT mice survival but CD40(-/-) hosts received no survival benefit. Conversely, attenuation of a therapeutic effect in mice treated with CD40(-/-) DCGs was not observed. The functional activities of NK and NKT cells in DCG-treated CD40(-/-) mice were partially suppressed.
Conclusion:
Host CD40 is essential for DCG treatment to have a therapeutic effect on B16F10 lung metastases.
